Pilot Study: Effectiveness of Different Kefir Formulations on Symptoms of Functional Constipation in Chilean Adults. (KEF-CON)

November 5, 2026 updated by: Cecilia Sepulveda

Evaluation of the Efficacy of Different Homemade Kefir Formulations in Improving Symptoms of Functional Chronic Constipation in Chilean Adults.

Functional chronic constipation is a common digestive disorder in Chilean adults. It causes infrequent or difficult bowel movements, abdominal discomfort and a feeling of incomplete evacuation, and it can impair quality of life. Kefir is a fermented milk made with grains that contain lactic acid bacteria and yeasts. It has been proposed as a dietary option to relieve constipation, but its effects may depend on how it is prepared.

The purpose of this study is to evaluate whether daily intake of two homemade kefir formulations, one made with whole milk and one made with skim milk, improves constipation symptoms and quality of life in adults with functional chronic constipation, compared with dietary counseling alone.

Thirty adults of both sexes diagnosed with functional chronic constipation according to the Rome IV criteria will be randomly assigned to one of three groups (10 per group):

Whole-milk kefir (KLE) Skim-milk kefir (KLD) Control group receiving nutritional counseling based on the Chilean Dietary Guidelines only

Participants in the kefir groups will follow a gradual dose increase (50, 100, 150 and up to 200 mL/day) for 4 weeks. Both kefir formulations will be prepared under standardized conditions (6% grain inoculation, 48-hour fermentation) and characterized for their nutritional, microbiological and sensory properties before the trial.

The primary outcome will be constipation-specific quality of life, measured with the PAC-QOL questionnaire. Secondary outcomes will include constipation symptoms (Rome IV criteria), stool consistency (Bristol Stool Form Scale) and generic health-related quality of life (EQ-5D). Dietary intake (24-hour recall and food frequency questionnaire) and physical activity (GPAQ) will be recorded as potential confounders. All assessments will be done before and after the intervention.

The researchers expect that participants who drink kefir will improve their constipation symptoms and quality of life more than those who receive counseling only. They also expect a greater improvement with the whole-milk kefir

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

57

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Huechuraba
      • Santiago, Huechuraba, Chile, 7750000
        • Recruiting
        • Universidad Mayor
        • Contact:
        • Contact:
        • Principal Investigator:
          • CECILIA A SEPULVEDA, MAGISTER EN NUTRICION

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 18 to 55 years.
  • Meet the Rome IV criteria for functional constipation, assessed using the Rome IV Diagnostic Questionnaire, with or without a previous medical diagnosis of chronic functional constipation. When a prior diagnosis is present, it is recorded as medical history, and the Rome IV criteria are verified independently.
  • Member of the Universidad Mayor Huechuraba campus community (students, faculty members, administrative staff, or support personnel).
  • No consumption of kefir, probiotics, prebiotics, or fermented dairy products during the 4 weeks prior to enrollment.
  • Have access to a home refrigerator and be available to attend weekly product distribution sessions and study assessments.

Exclusion Criteria:

  • Secondary constipation (organic, pharmacological, or metabolic) or acute constipation.
  • Chronic use of corticosteroids, antispasmodics, nonsteroidal anti-inflammatory drugs (NSAIDs), iron supplements, aluminum-containing antacids, opioids, calcium channel blockers, or immunotherapy.
  • Current antibiotic treatment or antibiotic use within the 4 weeks prior to enrollment.
  • Lactose intolerance, celiac disease, or cow's milk protein allergy.
  • Type 1 or Type 2 diabetes mellitus.
  • Hypothyroidism.
  • Chronic kidney disease.
  • Hypoparathyroidism.
  • Hypercalcemia.
  • Parkinson's disease.
  • History of stroke with residual neurological sequelae.
  • HIV infection.
  • Immunosuppression of any cause.
  • Irritable bowel syndrome.
  • Inflammatory bowel disease.
  • History of bariatric surgery.
  • History of colorectal surgery.
  • Pregnancy or lactation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Whole Milk Kefir (KLE)

Participants receive homemade kefir prepared with whole milk (6% grain inoculation, 48-hour fermentation), with an escalating daily dose of 50, 100, 150 and 200 mL. In addition to dietary counseling

Homemade kefir produced by fermenting whole milk with kefir grains (6% inoculation, 48-hour fermentation). Administered orally once daily for 1 month. The dose is escalated every 24 hours during the first 3 days (50 mL on day 1, 100 mL on day 2, 150 mL on day 3), reaching 200 mL/day from day 4, which is maintained until the end of the intervention. Differs from the skim milk formulation in fat content. In addition a dietary couselling

Single standardized nutritional counseling session for chronic functional constipation, delivered by a registered dietitian at baseline after randomization, including recommendations on dietary fiber, fluid intake and eating habits. Participants are followed for 1 month.

Experimental: Skim Milk Kefir (KLD)

Participants receive homemade kefir prepared with skim milk (6% grain inoculation, 48-hour fermentation), with an escalating daily dose of 50, 100, 150 and 200 mL. In addition to dietary counseling

Single standardized nutritional counseling session for chronic functional constipation, delivered by a registered dietitian at baseline after randomization, including recommendations on dietary fiber, fluid intake and eating habits. Participants are followed for 1 month.

Participants receive homemade skim milk kefir orally once daily for 1 month, with a dose escalated every 24 hours during the first 3 days (50, 100 and 150 mL) and maintained at 200 mL/day from day 4 until the end of the intervention.In addition a dietary couselling

Active Comparator: Dietary Counseling (Control)

Participants receive standardized dietary counseling for chronic functional constipation, without kefir supplementation.

Single standardized nutritional counseling session for chronic functional constipation, delivered by a registered dietitian at baseline after randomization, including recommendations on dietary fiber, fluid intake and eating habits. Participants are followed for 1 month.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in the Number of Rome IV Diagnostic Criteria for Functional Constipation Met at 1 Month
Time Frame: Baseline and 1 month (end of intervention)

Functional constipation symptoms were assessed with the Rome IV diagnostic criteria. Each participant was scored on six criteria: straining, lumpy or hard stools (Bristol Stool Form Scale types 1-2), sensation of incomplete evacuation, sensation of anorectal obstruction or blockage, and manual maneuvers to facilitate defecation, each present in more than 25% of defecations, plus fewer than 3 spontaneous bowel movements per week. The score ranges from 0 (minimum, no criteria met) to 6 (maximum, all criteria met). Higher scores indicate more severe constipation, which is a worse outcome. At baseline, criteria were assessed according to the Rome IV time requirement (symptoms present during the last 3 months, with onset at least 6 months before diagnosis). At the end of the intervention, they were assessed for the 1-month intervention period. The change from baseline (number of criteria at the end of the intervention minus baseline) was compared between the homemade whole-milk kefir group

Baseline and 1 month (end of intervention)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in the Patient Assessment of Constipation Quality of Life (PAC-QOL) Overall Score at 1 Month
Time Frame: Baseline and 1 month (end of intervention)

Constipation-specific quality of life was assessed with the Patient Assessment of Constipation Quality of Life questionnaire (PAC-QOL). It is a self-administered instrument of 28 items grouped into four subscales: physical discomfort (4 items), psychosocial discomfort (8 items), worries and concerns (11 items) and satisfaction (5 items). Each item is rated on a 5-point Likert scale from 0 to 4. The satisfaction items are reverse-scored. The overall score is the mean of all items, and each subscale score is the mean of its items. Overall and subscale scores range from 0 (minimum) to 4 (maximum). Higher scores indicate worse quality of life. The change from baseline (overall score at the end of the intervention minus baseline) was compared between the homemade whole-milk kefir group, the homemade skim-milk kefir group and the standard dietary counseling group. A negative change indicates improvement in quality of life.

Baseline and 1 month (end of intervention)
Change from Baseline in the Number of Bowel Movements per Week, as Recorded in a Self-Report Diary, at 1 Month
Time Frame: Baseline and 1 month (end of intervention)

Participants recorded each bowel movement in a self-report diary. Weekly bowel movement frequency was calculated as the number of bowel movements per week. The change from baseline (weekly frequency at the end of the intervention minus baseline) was compared in two ways: first, between each homemade kefir group (whole milk and skim milk) and the standard dietary counseling group; second, between the homemade whole-milk kefir group and the homemade skim-milk kefir group. A positive change indicates an increase in bowel movement frequency, which is a better outcome.

Baseline and 1 month (end of intervention)
Change from Baseline in Stool Consistency as Assessed by the Bristol Stool Form Scale at 1 Month
Time Frame: Baseline and 1 month (end of intervention)

Participants recorded each bowel movement in a self-report diary. For the end-of-intervention value, the mean number of bowel movements per week was calculated from all diary records over the entire 1-month intervention period. The change from baseline (mean weekly frequency over the intervention period minus baseline frequency) was compared in two ways: first, between each homemade kefir group (whole milk and skim milk) and the standard dietary counseling group; second, between the homemade whole-milk kefir group and the homemade skim-milk kefir group. A positive change indicates an increase in bowel movement frequency, which is a better outcome.

Unit of Measure:

bowel movements per week

Baseline and 1 month (end of intervention)
Change from Baseline in Health-Related Quality of Life as Assessed by the EQ-5D Index Score and EQ-5D Visual Analogue Scale (EQ VAS) at 1 Month
Time Frame: Baseline and 1 month ( end of intervention)

Health-related quality of life was assessed with the EuroQol 5-Dimension, 3-Level questionnaire (EQ-5D-3L), which has two components. The descriptive system covers five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each rated at three levels (no problems, some problems, extreme problems). Responses were converted into a single index score using the Chilean time trade-off value set (Zarate et al., 2011). The index ranges from [value of minimum; values below 0 represent health states considered worse to 1 maximum; full health. The visual analogue scale (EQ VAS) records self-rated health on the day of assessment, from 0 (minimum; worst imaginable health) to 100 (maximum; best imaginable health). For both components, higher scores indicate better health status. The change from baseline (score at the end of the intervention minus baseline) was compared for each component in two ways: first, between each homemade kefir

Baseline and 1 month ( end of intervention)
Sensory Acceptability of Homemade Whole-Milk and Skim-Milk Kefir as Assessed by a 7-Point Hedonic Scale at 1 Month
Time Frame: 1 month (end of intervention)

Sensory acceptability of the homemade kefir was assessed at the end of the intervention with a 7-point hedonic scale (Likert type) in participants allocated to the whole-milk or skim-milk kefir groups. Participants rated each sensory attribute (appearance, color, aroma, flavor, texture and overall acceptability) from 1 (minimum; dislike very much) to 7 (maximum; like very much), with 4 representing neither like nor dislike. Each attribute was scored separately. Higher scores indicate greater acceptability, which is a better outcome. The scores for each attribute were compared between the homemade whole-milk kefir group and the homemade skim-milk kefir group. Participants in the standard dietary counseling group did not consume kefir and were not assessed.

Unit of Measure:

score on a scale

1 month (end of intervention)
Adherence to Homemade Kefir Consumption, Measured as the Percentage of Prescribed Daily Doses Consumed and Recorded in a Self-Report Log, Over 1 Month
Time Frame: From day 1 to 1 month (entire intervention period)

Adherence was assessed in participants allocated to the whole-milk or skim-milk kefir groups using a self-report log. Each day, participants recorded whether the prescribed daily dose was consumed or not consumed. The prescribed dose escalated over the first three days (50 mL on day 1, 100 mL on day 2 and 150 mL on day 3) and was then 200 mL/day from day 4 until the end of the intervention. Adherence was calculated as the number of daily doses consumed divided by the total number of prescribed daily doses, multiplied by 100. Scores range from 0% (minimum) to 100% (maximum). Higher percentages indicate greater adherence, which is a better outcome. Adequate adherence was defined as consuming at least 80% of the prescribed daily doses. Adherence was compared between the homemade whole-milk kefir group and the homemade skim-milk kefir group. Participants in the standard dietary counseling group did not consume kefir and were not assessed.

Unit percentage of prescribed daily doses

From day 1 to 1 month (entire intervention period)
Incidence of adverse events
Time Frame: Weekly, from day 1 to 1 month (entire intervention period)

Adverse events were recorded weekly throughout the intervention in participants allocated to the whole-milk or skim-milk kefir groups. Gastrointestinal adverse events included bloating, flatulence, abdominal pain or cramping, nausea and diarrhea. Any other adverse event reported by participants was also recorded. Each event was classified by severity (mild, moderate or severe) and by its relationship to kefir consumption (related or not related). The number and percentage of participants with at least one adverse event, overall, by type of event, by severity and by relationship to kefir, were compared between the homemade whole-milk kefir group and the homemade skim-milk kefir group. Adverse events were not recorded in the standard dietary counseling group, because its participants did not receive kefir.

Unit of Measure:

participants

Weekly, from day 1 to 1 month (entire intervention period)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: CECILIA A SEPULVEDA, MAGISTER EN NUTRICION, Universidad Mayor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 20, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

October 21, 2026

First Submitted That Met QC Criteria

November 5, 2026

First Posted (Actual)

November 10, 2026

Study Record Updates

Last Update Posted (Actual)

November 10, 2026

Last Update Submitted That Met QC Criteria

November 5, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 973/2026
  • 0738 (Other Identifier: COMITE DE ETICA UNIVERSIDAD MAYOR)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.